UNLEASH THE POWER OF PRECISION MEDICINE

Transcription

1 FROM BENCH TO BEDSIDE UNLEASH THE POWER OF PRECISION MEDICINE DCB, pioneer in biotech. Your partner in drug discovery.

2 The Center for Biotechnology With over 400 dedicated researchers and state-of-the-art facilities, the Center for Biotechnology (DCB) specializes in developing biologics and small molecule drugs, botanical drugs, as well as technologies required for preclinical testing. Our expertise arises from the integration of a number of diverse disciplines, including biology, chemistry, protein purification and engineering, as well as analytical and quality assurance. Established in 1984 by Taiwan s Ministry of Economic Affairs (MOEA), Department of Industrial Technology (DoIT), DCB was initially tasked with establishing the biotechnology industry in Taiwan. Through strategic global alliances and technology transfer agreements, DCB has successfully fostered the development of a complete biotech infrastructure and value chain, as well as a diverse array of applications for use by the private sector. As a result, DCB has become one of Taiwan s most important research institutes. Mission & Aim Improving the quality of life for the people of Taiwan and the world. DCB s mission is to facilitate the ongoing growth and development Taiwan s biotechnology industry. To this end, we strive to act as the industry s partner, coordinating resources among government, academia and private companies. DCB remains a key force in building and upgrading Taiwan s biomedical infrastructure, developing key technologies, and growing Taiwan s professional workforce. Our ultimate aim is to improve the quality of life for the people of Taiwan and the world. To this end, DCB fosters international partnerships and collaborations with research institutes and global biopharmaceuticals throughout Asia and the world.

3 Integrated capabilities and full scale services for new drug discovery From bench to bedside Biologics Pharmaceutics Pharmacology

4 Institute of Biologics DCB s Institute of Biologics is devoted to developing therapeutic antibodies and next generation biologics, such as bi-specific antibodies (BsAb) and antibody-drug conjugates (ADC). Our integrated capabilities in antibody drug development, from antibody library construction and screening, humanization, affinity maturation, cell line development, pharmacology, and zpk/pd to toxicology, combined with our on-site cgmp manufacturing capabilities have allowed us to create a number of unique biologics candidates. These include anti-globo H mab, anti-globo H x anti-cd3 BsAb, anti-il20 mab, anti-tim3 mab, and a number of others. In addition to new drug development, the Institute of Biologics also provides services to the academic community and biotechnology industry. These services include antibody screening and engineering, cell line development, protein expression, process development, functional assays, protein characterization and cell line engineering. Antibody Antibody Screening Optimization Preclinical Candidate Antibody Protein Engineering Protein Expression Protein Characterization BioEngineering Ab library construction, phage display, Ab screening and generation, affinity evaluation Human Ab from single B cell Ab optimization, computer modeling, humanization, affinity maturation, BsAb engineering Small scale protein expression and purification (5L), Cell line development (ClonePix2) Medium optimization, process development (minibioreactor) Sturctural characterization and confirmation Physicochemical properties analysis: e.g., purity, integrity, size, identity Process- and product-related impurities analysis Preformulation/Formulation and stability studies Cell engineering (high production cell line e.g. CHO cell, microbe, novel engineered host and vector) Metabolic engineering Scale-down process development Novel bioproduction technologies (continuous bioprocess) IND Filing

5 Institute of Pharmaceutics DCB s Institute of Pharmaceutics is dedicated to the development of small molecule drugs and therapeutic technologies that are improvements and optimizations of existing drug molecules. The Institute of Pharmaceutics comprises two core groups: Pharmaceutics and Botanical Drugs. With over 70 researchers specializing in medicinal chemistry, the Pharmaceutics Group focuses on target discovery and validation; hit finding; lead compounds identification; synthesis and optimization; pharmacokinetic study design and interpretation; drug stability profiles; and off-target toxicity analysis. Importantly, we also possess proprietary ADC technologies that combine site-specific conjugation with proprietary linkers and payloads optimized for safety, efficacy and biophysical properties. Our Botanical Drugs Group specializes in natural-product formulation, plant authentication, and CMC (chemistry, manufacturing, and control) for botanical drugs and natural products. The Botanical Drugs Group can provide integrative services from material development and DNA identification to consultation for Investigational New Drug (IND) submissions as well as CMC. Candidate Selection Target Validation Optimization Hit to Medicinal Chemistry Ligand-based/structure-based rational drug design Computer modeling Drug Analysis & Formulation Preformulation Formulation In Vitro Biology In vitro assays Mode of action analysis Botanical Drug Botanical drug R&D Services for IND submission and CMC chonsultation Preclinical IND Filing

6 Institute of Pharmacology & Drug Disposition The researchers at the Institute of Pharmacology & Drug Disposition have extensive research experience and expertise in investigational new drug (IND) application management. The Institute has three core groups, DMPK, Pharmacology and IND Core, which can provide a wide range of services from initial early assessments of ADME (absorption, distribution, metabolism and excretion), pharmacology, to consultation on regulatory IND. The DMPK group offers comprehensive testing services in drug metabolism and pharmacokinetics by utilizing various administration routes and dosing regimens, with studies that fully comply with Taiwan s FDA GLP regulations. The Pharmacology Group specializes in cancer, immune responses, inflammation, metabolism, and respiratory diseases, and can provide professional support in the selection of appropriate models and assays. Most importantly, by combining genetic and genomic technologies, as well as comparative medicine data, the group can conduct comprehensive biomarker analysis that greatly enhances drug therapeutic efficacy. The IND Core offers expert assistance to biotechnology and pharmaceutical companies, and academia in planning and implementing the filing of IND applications, as well as the preparation of documentation required for pre-ind and IND submissions. Identification Target Validation Drug Metabolism & Pharmacokinetics Pharmacology IND Core Team IND Filing Optimization Preclinical Candidate Selection Biologics analysis Bio analysis In vitro ADME Metabolism PK Animal models Biomarkers In silico analysis Bioinformatics Project management

7 Business Services DCB s Business Services unit is the Institute s business core. We provide integrated services, including market intelligence and research, IP protection, startup incubation, talent cultivation, technology valuation and transfer, international cooperation, as well as marketing and promotion. We are your one-stop service window for all business related affairs. DCB s Business Services unit also acts as a think tank for the government, scouting out emerging global biotechnology trends and providing the governement with market forecasts and reports for developing national policies in the biomedical industry. Contact Us: Arthur Chen Director of Business arthur.chen@dcb.org.tw No. 101, Lane 169, Kang-ning Street, Xizhi Dist., New Taipei City, Taiwan IP Protection Startup Incubation Market Intelligence Business Integrated Marketing International Cooperation Tech Valuation and Transfer